English
简体中文
Total: £ 56.28
Published Date: 2025-05-06 | Pages: 89 | Tables: 89 | Pharma & Healthcare
The global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications was valued at US$ 23480 million in the year 2024 and is projected to reach a revised size of US$ 32450 million by 2031, growing at a CAGR of 4.8% during the forecast period.
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 Market by Application
1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Perspective (2020-2031)
2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Growth Trends by Region
2.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Region (2020-2025)
2.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2026-2031)
2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Dynamics
2.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
2.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
2.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
2.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue
3.1.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue (2020-2025)
3.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Players (2020-2025)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue
3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio
3.4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2024
3.5 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Head office and Area Served
3.6 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Product and Application
3.7 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Type
4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Type (2020-2025)
4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2026-2031)
5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Application
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Application (2020-2025)
5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2020-2031)
6.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025)
6.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2020-2031)
7.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025)
7.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2020-2031)
8.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2020-2025)
8.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2020-2031)
9.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025)
9.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2020-2031)
10.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025)
10.4 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.1.4 Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Dako (Agilent Technologies)
11.2.1 Dako (Agilent Technologies) Company Details
11.2.2 Dako (Agilent Technologies) Business Overview
11.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.2.4 Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.2.5 Dako (Agilent Technologies) Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.3.4 Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.3.5 Merck Recent Development
11.4 BD
11.4.1 BD Company Details
11.4.2 BD Business Overview
11.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.4.4 BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.4.5 BD Recent Development
11.5 Abbott
11.5.1 Abbott Company Details
11.5.2 Abbott Business Overview
11.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.5.4 Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.5.5 Abbott Recent Development
11.6 Genesys Biolabs (20/20GeneSystems)
11.6.1 Genesys Biolabs (20/20GeneSystems) Company Details
11.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
11.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.6.4 Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.6.5 Genesys Biolabs (20/20GeneSystems) Recent Development
11.7 Affymetrix
11.7.1 Affymetrix Company Details
11.7.2 Affymetrix Business Overview
11.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.7.4 Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.7.5 Affymetrix Recent Development
11.8 Agendia
11.8.1 Agendia Company Details
11.8.2 Agendia Business Overview
11.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.8.4 Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.8.5 Agendia Recent Development
11.9 ALMAC
11.9.1 ALMAC Company Details
11.9.2 ALMAC Business Overview
11.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.9.4 ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.9.5 ALMAC Recent Development
11.10 Arrayit
11.10.1 Arrayit Company Details
11.10.2 Arrayit Business Overview
11.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.10.4 Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.10.5 Arrayit Recent Development
11.11 Biocartic
11.11.1 Biocartic Company Details
11.11.2 Biocartic Business Overview
11.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.11.4 Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.11.5 Biocartic Recent Development
11.12 BG Medicine
11.12.1 BG Medicine Company Details
11.12.2 BG Medicine Business Overview
11.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.12.4 BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.12.5 BG Medicine Recent Development
11.13 KEGG EXPRESSION Database
11.13.1 KEGG EXPRESSION Database Company Details
11.13.2 KEGG EXPRESSION Database Business Overview
11.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.13.4 KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.13.5 KEGG EXPRESSION Database Recent Development
11.14 Thermo Fisher
11.14.1 Thermo Fisher Company Details
11.14.2 Thermo Fisher Business Overview
11.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.14.4 Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.14.5 Thermo Fisher Recent Development
11.15 BGI
11.15.1 BGI Company Details
11.15.2 BGI Business Overview
11.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.15.4 BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
11.15.5 BGI Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Consumables
Table 3. Key Players of Services
Table 4. Key Players of Software
Table 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2020-2025)
Table 9. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2026-2031)
Table 11. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Trends
Table 12. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
Table 13. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
Table 14. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
Table 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Players (2020-2025)
Table 17. Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2024)
Table 18. Ranking of Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Headquarters and Area Served
Table 21. Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Product and Application
Table 22. Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2020-2025)
Table 26. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2026-2031)
Table 28. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Application (2020-2025)
Table 30. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Application (2026-2031)
Table 32. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2026-2031) & (US$ Million)
Table 47. Roche Company Details
Table 48. Roche Business Overview
Table 49. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 50. Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Dako (Agilent Technologies) Company Details
Table 53. Dako (Agilent Technologies) Business Overview
Table 54. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 55. Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 56. Dako (Agilent Technologies) Recent Development
Table 57. Merck Company Details
Table 58. Merck Business Overview
Table 59. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 60. Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 61. Merck Recent Development
Table 62. BD Company Details
Table 63. BD Business Overview
Table 64. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 65. BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 66. BD Recent Development
Table 67. Abbott Company Details
Table 68. Abbott Business Overview
Table 69. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 70. Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 71. Abbott Recent Development
Table 72. Genesys Biolabs (20/20GeneSystems) Company Details
Table 73. Genesys Biolabs (20/20GeneSystems) Business Overview
Table 74. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 75. Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 76. Genesys Biolabs (20/20GeneSystems) Recent Development
Table 77. Affymetrix Company Details
Table 78. Affymetrix Business Overview
Table 79. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 80. Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 81. Affymetrix Recent Development
Table 82. Agendia Company Details
Table 83. Agendia Business Overview
Table 84. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 85. Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 86. Agendia Recent Development
Table 87. ALMAC Company Details
Table 88. ALMAC Business Overview
Table 89. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 90. ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 91. ALMAC Recent Development
Table 92. Arrayit Company Details
Table 93. Arrayit Business Overview
Table 94. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 95. Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 96. Arrayit Recent Development
Table 97. Biocartic Company Details
Table 98. Biocartic Business Overview
Table 99. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 100. Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 101. Biocartic Recent Development
Table 102. BG Medicine Company Details
Table 103. BG Medicine Business Overview
Table 104. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 105. BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 106. BG Medicine Recent Development
Table 107. KEGG EXPRESSION Database Company Details
Table 108. KEGG EXPRESSION Database Business Overview
Table 109. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 110. KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 111. KEGG EXPRESSION Database Recent Development
Table 112. Thermo Fisher Company Details
Table 113. Thermo Fisher Business Overview
Table 114. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 115. Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 116. Thermo Fisher Recent Development
Table 117. BGI Company Details
Table 118. BGI Business Overview
Table 119. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 120. BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025) & (US$ Million)
Table 121. BGI Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
Table 125. Authors List of This Report
List of Figures
Figure 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture
Figure 2. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type: 2024 VS 2031
Figure 4. Consumables Features
Figure 5. Services Features
Figure 6. Software Features
Figure 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application: 2024 VS 2031
Figure 9. Oncology Case Studies
Figure 10. Cardiology Case Studies
Figure 11. Neurology Case Studies
Figure 12. Other Case Studies
Figure 13. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report Years Considered
Figure 14. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region: 2024 VS 2031
Figure 17. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Players in 2024
Figure 18. Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2024
Figure 20. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2020-2031)
Figure 22. United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2020-2031)
Figure 26. Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2020-2031)
Figure 34. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2020-2031)
Figure 42. Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2020-2031)
Figure 46. Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Roche Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 50. Dako (Agilent Technologies) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 51. Merck Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 52. BD Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 53. Abbott Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 54. Genesys Biolabs (20/20GeneSystems) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 55. Affymetrix Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 56. Agendia Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 57. ALMAC Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 58. Arrayit Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 59. Biocartic Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 60. BG Medicine Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 61. KEGG EXPRESSION Database Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 62. Thermo Fisher Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 63. BGI Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
